Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2019 Dec 11. doi: 10.1007/s00259-019-04614-y. [Epub ahead of print]

[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Author information

1
MNM AOU S.Orsola-Malpighi, Bologna, Italy. cristina.nanni@aosp.bo.it.
2
MNM AOU S.Orsola-Malpighi, Bologna, Italy.
3
Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
4
Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland.
5
PET-Centre, University Hospital of North Norway, Tromso, Norway.
6
Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, Denmark.
7
Department of Radiology and Imaging Services, Emory University, Atlanta, GA, USA.
8
Division of Nuclear Medicine, Department of Radiology, Loyola University Medical Center, Maywood, IL, USA.
9
Department of Oncology, University of Oxford, Oxford, UK.
10
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.

Abstract

The aim of this guideline is to provide standards for the recommendation, performance, interpretation, and reporting of [18F]Fluciclovine PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of [18F]Fluciclovine PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.

KEYWORDS:

Guideline; PET; Prostate cancer; Restaging; Staging; [18F]Fluciclovine

PMID:
31822959
DOI:
10.1007/s00259-019-04614-y

Supplemental Content

Full text links

Icon for Springer Icon for Norwegian BIBSYS system
Loading ...
Support Center